

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for January 2020

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Darunavir	Prezista	Darunavir	600 mg	tablet	02487241
Apotex Inc.	Apo-Darunavir	Prezista	Darunavir	800mg	tablet	02487268
Natco Pharma (Canada) Inc.	Nat-Pregabalin	Lyrica	pregabalin	25mg	capsule	02494841
Natco Pharma (Canada) Inc.	Nat-Pregabalin	Lyrica	pregabalin	50mg	capsule	02494868
Natco Pharma (Canada) Inc.	Nat-Pregabalin	Lyrica	pregabalin	75mg	capsule	02494876

Natco Pharma (Canada) Inc.	Nat-Pregabalin	Lyrica	pregabalin	150mg	capsule	02494884
Natco Pharma (Canada) Inc.	Nat-Pregabalin	Lyrica	pregabalin	300mg	capsule	02494906
Pharmascience Inc.	Pms-Efavirenz-Emtricitabine-Tenofovir	Atripla	efavirenz / emtricitabine / tenofovir disoproxil fumarate	600mg/ 200mg/ 300mg	FC tablet	02487284
Jamp Pharma Corporation	Jamp Dorzolamide-Timolol	Cosopt	dorzolamide HCl & timolol	2% & 5%	ophthalmic solution	02457539
Jamp Pharma Corporation	Jamp-Dorzolamide	Trusopt	dorzolamide HCl	2%	ophthalmic solution	02453347